BAX
Price
$23.80
Change
-$0.38 (-1.57%)
Updated
Sep 11, 04:59 PM (EDT)
Capitalization
12.5B
48 days until earnings call
Intraday BUY SELL Signals
XRAY
Price
$10.38
Change
-$0.11 (-1.05%)
Updated
Sep 11, 02:07 PM (EDT)
Capitalization
2.1B
48 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

BAX vs XRAY

BAX vs XRAY Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
BAX vs. XRAY commentary
Sep 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a StrongBuy and XRAY is a Hold.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BAX($12.5B) has a higher market cap than XRAY($2.1B). BAX YTD gains are higher at: 26.707 vs. XRAY (-8.136). BAX has higher annual earnings (EBITDA): 762M vs. XRAY (93M). BAX has more cash in the bank: 2.15B vs. XRAY (239M). XRAY has less debt than BAX: XRAY (2.31B) vs BAX (9.67B). BAX has higher revenues than XRAY: BAX (11.5B) vs XRAY (3.64B).
BAXXRAYBAX / XRAY
Capitalization12.5B2.1B597%
EBITDA762M93M819%
Gain YTD26.707-8.136-328%
P/E Ratio87.85N/A-
Revenue11.5B3.64B316%
Total Cash2.15B239M900%
Total Debt9.67B2.31B418%
FUNDAMENTALS RATINGS
BAX vs XRAY: Fundamental Ratings
BAX
XRAY
OUTLOOK RATING
1..100
5863
VALUATION
overvalued / fair valued / undervalued
1..100
98
Overvalued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9497
PRICE GROWTH RATING
1..100
4661
P/E GROWTH RATING
1..100
2681
SEASONALITY SCORE
1..100
8585

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

XRAY's Valuation (3) in the Medical Specialties industry is significantly better than the same rating for BAX (98). This means that XRAY’s stock grew significantly faster than BAX’s over the last 12 months.

XRAY's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as BAX (100). This means that XRAY’s stock grew similarly to BAX’s over the last 12 months.

BAX's SMR Rating (94) in the Medical Specialties industry is in the same range as XRAY (97). This means that BAX’s stock grew similarly to XRAY’s over the last 12 months.

BAX's Price Growth Rating (46) in the Medical Specialties industry is in the same range as XRAY (61). This means that BAX’s stock grew similarly to XRAY’s over the last 12 months.

BAX's P/E Growth Rating (26) in the Medical Specialties industry is somewhat better than the same rating for XRAY (81). This means that BAX’s stock grew somewhat faster than XRAY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BAXXRAY
RSI
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 2 days ago
71%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
47%
Momentum
ODDS (%)
Bearish Trend 2 days ago
71%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
52%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
70%
Bearish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 24 days ago
57%
Bullish Trend 9 days ago
57%
Declines
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
73%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
64%
Bullish Trend 2 days ago
45%
Aroon
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 2 days ago
73%
COMPARISON
Comparison
Sep 11, 2026
Stock price -- (BAX: $24.18 vs. XRAY: $10.50)
Brand notoriety: BAX and XRAY are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: BAX: 91% vs. XRAY: 85%
Market capitalization -- BAX: $12.5B vs. XRAY: $2.1B
BAX [@Pharmaceuticals: Other] is valued at $12.5B. XRAY’s [@Pharmaceuticals: Other] market capitalization is $2.1B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $126 to $124.79B. The average market capitalization across the [@Pharmaceuticals: Other] industry is $8.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BAX’s FA Score shows that 1 FA rating(s) are green while XRAY’s FA Score has 1 green FA rating(s).

  • BAX’s FA Score: 1 green, 4 red.
  • XRAY’s FA Score: 1 green, 4 red.
According to our system of comparison, BAX is a better buy in the long-term than XRAY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BAX’s TA Score shows that 3 TA indicator(s) are bullish while XRAY’s TA Score has 6 bullish TA indicator(s).

  • BAX’s TA Score: 3 bullish, 6 bearish.
  • XRAY’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, XRAY is a better buy in the short-term than BAX.

Price Growth

BAX (@Pharmaceuticals: Other) experienced а -5.44% price change this week, while XRAY (@Pharmaceuticals: Other) price change was -8.14% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -3.54%. For the same industry, the average monthly price growth was -3.49%, and the average quarterly price growth was +12.65%.

Reported Earning Dates

BAX is expected to report earnings on Oct 29, 2026.

XRAY is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Pharmaceuticals: Other (-3.54% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

View a ticker or compare two or three
BAX
Daily Signal:
Gain/Loss:
XRAY
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
EPMV27.07N/A
N/A
Harbor Mid Cap Value ETF
FBUF33.28-0.07
-0.19%
Fidelity Dynamic Buffered Equity ETF
GUSE45.10-0.31
-0.67%
Goldman Sachs Enhanced U.S. Equity ETF
LMUB47.74-0.50
-1.04%
iShares Long-Term National Muni Bd ETF
ACEP20.31-0.26
-1.28%
ARS Core Equity ETF

XRAY and

Correlation & Price change

A.I.dvisor indicates that over the last year, XRAY has been loosely correlated with NVST. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if XRAY jumps, then NVST could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XRAY
1D Price
Change %
XRAY100%
-2.05%
NVST - XRAY
62%
Loosely correlated
-2.08%
ALGN - XRAY
58%
Loosely correlated
-1.44%
QDEL - XRAY
50%
Loosely correlated
-3.88%
KIDS - XRAY
48%
Loosely correlated
-0.55%
BAX - XRAY
46%
Loosely correlated
-0.86%
More